Better questions create better animal-health partnerships.

A useful brief identifies the destination market, animal species and life stage, intended product positioning, dosage form, pack size, target cost, forecast volume and launch timing. It should separate desired ingredients from non-negotiable specifications and explain which party will own the formula, artwork and market review. Buyers should also state required testing, documentation, sample stages and approval contacts. This gives the manufacturer enough information to flag feasibility and regulatory questions before pricing or pilot work begins.

No. A commercial description such as “pet supplement” does not determine the legal classification. Classification can depend on ingredients, intended use, claims, presentation and destination-country rules. In the United States, the human dietary-supplement framework does not automatically apply to animal products; depending on intended use, a product may be regulated as animal food or as a new animal drug. The importer should obtain a market-specific classification review before finalising formula, claims, label or launch plan.

Start with the animal, serving size, ingredient loading, stability and how the owner is expected to administer the product. Soft chews can support an easy daily routine but place constraints on moisture, texture and palatability. Tablets and capsules offer dose precision; powders can suit larger servings; liquids can support flexible dosing but require careful preservation and packaging review. The final choice should be tested against formula compatibility, target shelf life, pack cost and the customer experience—not selected on appearance alone.

Ask how the supplier defines acceptance, which species and population were evaluated, the number of animals, test conditions and whether results relate to the final formula and dosage form. Palatability can change when active ingredients, flavours, coating, hardness, moisture or serving size change. A sensible approval plan includes a physical sample review and, where commercially important, a documented acceptance study using the final or representative product. Palatability results should not be converted into health or efficacy claims.

Build an ingredient matrix showing the exact substance, source, grade, specification, function, use level and target species. Then check each item against the destination market’s recognised ingredient pathways and restrictions. A familiar ingredient name is not enough: source, processing method, purity, carrier and intended use can change the assessment. Complete this review before artwork and commercial production, and record unresolved items for a qualified regulatory reviewer or the competent authority.

A practical pre-order pack normally includes the approved formula or composition statement, finished-product specification, sample certificate of analysis, ingredient specifications, packaging specification, label draft, shelf-life support, manufacturing-site information and applicable quality certificates. Depending on market and risk, buyers may also request contaminant, microbiological, identity or stability evidence. Documents should identify the product and revision clearly. Certificates are supporting evidence, not substitutes for destination-market classification or importer due diligence.

The specification defines the agreed acceptance criteria for the product—such as identity, physical attributes, nutrient or active ranges, microbiological limits and packaging requirements. A certificate of analysis reports results or confirmations for a particular batch against those criteria. Buyers should agree which tests are performed per batch, which are verified periodically and which methods apply. A COA should be traceable to the product code, lot and manufacture or release date; it should not be treated as a general marketing certificate.

Shelf life should be supported by a documented stability rationale or study for the final formula in the proposed packaging. The protocol should define storage conditions, time points, tested attributes and acceptance limits. Buyers should ask whether evidence is real-time, accelerated or bridged from a sufficiently comparable product, and what happens if the formula, flavour, dosage form or pack changes. A printed expiry or best-before date is the output of this assessment, not the evidence itself.

Packaging is part of the product system. Moisture, oxygen, light, heat and repeated opening can affect texture, flavour, microbial risk and ingredient stability. Buyers should confirm material structure, closure, seal, headspace, desiccant or induction-seal needs, transport durability and compatibility with the formula. The selected pack should be represented in shelf-life work. Artwork must also leave enough space for mandatory information and market-specific warnings without reducing legibility.

Requirements vary, but common elements include product identity, net quantity, the name and place of business of the manufacturer or distributor, and an ingredient list. In the United States, ingredients are generally declared by common or usual name in descending order by weight, and state rules may also apply. Species, directions, lot identification, date marking and storage statements may be important depending on the product and market. The local brand owner or importer should approve a market-specific label before printing.

Claims communicate intended use and can change how a regulator classifies a product. In the United States, statements that a product will cure, treat, prevent or mitigate disease—or certain non-food effects on body structure or function—may indicate a new animal drug. Even a truthful ingredient statement does not automatically make every benefit claim permissible. Review the product name, front-panel copy, icons, testimonials, website text and social content together, because the overall presentation matters.

A product represented as complete and balanced is intended to provide total daily nutrition for a stated life stage and must be supported through an accepted nutritional-adequacy pathway in the relevant market. Treats, snacks and supplements are generally not designed to be the sole diet. Buyers should avoid copying complete-diet language onto a complementary product and should make feeding directions clear. The distinction affects formulation, substantiation, label language and how customers understand the product.

The brief and label should identify the intended species and relevant life stage or weight range. Directions need to be practical for the dosage form, consistent with the formula and expressed in units customers can measure reliably. Avoid assuming that a formula or serving suitable for dogs is automatically appropriate for cats, horses or birds. Any special-population caution, maximum use level or veterinarian-consultation statement should be determined through product and market review, then controlled across every language version.

The supplier should be able to connect the finished-product lot to incoming-material lots, production and packaging records, release status and distribution information. Buyers should agree the lot-code format, record-retention period, retained-sample practice and response time for a trace request. A mock recall or trace exercise is a useful audit topic. Traceability does not eliminate risk, but it makes investigation, containment and communication more controlled if a quality or safety issue occurs.

Ask what drives the minimum: ingredient purchase quantities, tooling, packaging print runs, line setup or testing. Separate the minimum manufacturing batch from the minimum quantity of custom packaging. A pilot may use stock packaging or digital labels, but the buyer should document which attributes differ from the intended commercial product. Evaluate unit cost together with expiry exposure, freight, launch forecast and the cost of future changes; the lowest nominal MOQ is not always the lowest-risk option.

Identify the sample version, formula revision, process scale, packaging and date. Record acceptance criteria for appearance, odour, flavour or acceptance, dimensions, weight, dispersion and any analytical attributes relevant to the product. Approval should state whether it covers only sensory characteristics or also the final specification and artwork. If commercial scale changes the equipment, ingredient source or pack, define which checks must be repeated before the first production lot is released.

The contract should assign responsibility for regulatory text, design, translation, proofreading, barcode ownership and final print approval. The manufacturer can provide product and production data, while the importer or brand owner usually brings destination-market and commercial context. Use controlled artwork files with revision numbers and an approval record. Machine translation alone is not sufficient for safety-critical directions or legal wording; qualified local review should occur before labels, cartons and online listings are released.

The Foreign Supplier Verification Programs rule can apply to U.S. importers of human and animal food. Its purpose is to help ensure imported food meets applicable U.S. requirements. Importers may need a hazard analysis, supplier evaluation, verification activities and records; the exact obligations and exemptions depend on the facts. Supplier certificates alone do not complete the importer’s program. The U.S. importer should determine its role early and build required verification into sourcing, audit and document requests.

A risk-based audit can review facility registration or licensing where applicable, material controls, sanitation, allergen or cross-contact controls, process controls, testing, release, traceability, complaints, recall readiness, training and change control. The buyer should verify that certificates match the legal entity, address, product scope and validity period. Remote evidence can support qualification, but it should not be mistaken for an on-site observation. Findings need owners, deadlines and documented closure.

A quality agreement turns expectations into assigned responsibilities. It can define specifications, release authority, approved suppliers, deviations, out-of-specification handling, change notification, complaints, adverse-event escalation, traceability, recalls, document access and retention. It should align with—rather than contradict—the commercial supply contract. The agreement is especially valuable when brand owner, importer and manufacturer are different entities, because it makes clear who decides, records and communicates at each quality stage.